A Phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma and a phase i study of crizotinib for recurrent or refractory neuroblastoma: Study protocol for a multicenter single-arm open-label trial

Masahiro Sekimizu, Tomoo Osumi, Reiji Fukano, Yuhki Koga, Akiko Kada, Akiko M. Saito, Tetsuya Mori

研究成果: ジャーナルへの寄稿記事

2 引用 (Scopus)

抄録

Crizotinib is an inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase (ALK). Responses to crizotinib have also been reported in patients with ALK-positive anaplastic large-cell lymphoma (ALCL) and solid tumors with ALK-mutation, including neuroblastoma. Optimal treatment for patients with recurrent or refractory ALK-positive ALCL and neuroblastoma has not been established. There is a need to develop new drugs for these patients. The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II).

元の言語英語
ページ(範囲)431-436
ページ数6
ジャーナルActa medica Okayama
72
発行部数4
出版物ステータス出版済み - 1 1 2018

Fingerprint

Anaplastic Large-Cell Lymphoma
Neuroblastoma
Refractory materials
Labels
Protein-Tyrosine Kinases
crizotinib
anaplastic lymphoma kinase
Tumors
Safety
Mutation
Pharmaceutical Preparations
Neoplasms

All Science Journal Classification (ASJC) codes

  • Biochemistry, Genetics and Molecular Biology(all)

これを引用

@article{0b5db9c3aaff47bd84fbcb5b1e4eb6e1,
title = "A Phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma and a phase i study of crizotinib for recurrent or refractory neuroblastoma: Study protocol for a multicenter single-arm open-label trial",
abstract = "Crizotinib is an inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase (ALK). Responses to crizotinib have also been reported in patients with ALK-positive anaplastic large-cell lymphoma (ALCL) and solid tumors with ALK-mutation, including neuroblastoma. Optimal treatment for patients with recurrent or refractory ALK-positive ALCL and neuroblastoma has not been established. There is a need to develop new drugs for these patients. The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II).",
author = "Masahiro Sekimizu and Tomoo Osumi and Reiji Fukano and Yuhki Koga and Akiko Kada and Saito, {Akiko M.} and Tetsuya Mori",
year = "2018",
month = "1",
day = "1",
language = "English",
volume = "72",
pages = "431--436",
journal = "Acta Medica Okayama",
issn = "0386-300X",
publisher = "Okayama University",
number = "4",

}

TY - JOUR

T1 - A Phase I/II study of crizotinib for recurrent or refractory anaplastic lymphoma kinase-positive anaplastic large cell lymphoma and a phase i study of crizotinib for recurrent or refractory neuroblastoma

T2 - Study protocol for a multicenter single-arm open-label trial

AU - Sekimizu, Masahiro

AU - Osumi, Tomoo

AU - Fukano, Reiji

AU - Koga, Yuhki

AU - Kada, Akiko

AU - Saito, Akiko M.

AU - Mori, Tetsuya

PY - 2018/1/1

Y1 - 2018/1/1

N2 - Crizotinib is an inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase (ALK). Responses to crizotinib have also been reported in patients with ALK-positive anaplastic large-cell lymphoma (ALCL) and solid tumors with ALK-mutation, including neuroblastoma. Optimal treatment for patients with recurrent or refractory ALK-positive ALCL and neuroblastoma has not been established. There is a need to develop new drugs for these patients. The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II).

AB - Crizotinib is an inhibitor of multiple tyrosine kinases, including the anaplastic lymphoma kinase (ALK). Responses to crizotinib have also been reported in patients with ALK-positive anaplastic large-cell lymphoma (ALCL) and solid tumors with ALK-mutation, including neuroblastoma. Optimal treatment for patients with recurrent or refractory ALK-positive ALCL and neuroblastoma has not been established. There is a need to develop new drugs for these patients. The objectives of this trial are to evaluate the tolerability and safety of crizotinib in Japanese patients with recurrent/refractory ALK-positive ALCL or neuroblastoma (phase I) and its efficacy in recurrent/refractory ALK-positive ALCL (phase II).

UR - http://www.scopus.com/inward/record.url?scp=85051865885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85051865885&partnerID=8YFLogxK

M3 - Article

C2 - 30140094

AN - SCOPUS:85051865885

VL - 72

SP - 431

EP - 436

JO - Acta Medica Okayama

JF - Acta Medica Okayama

SN - 0386-300X

IS - 4

ER -